Author:
Søltoft Frans,Hammer Mette,Kragh Nana
Publisher
Springer International Publishing
Reference21 articles.
1. Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E., et al. (2011). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity.https://doi.org/10.1038/ijo.2011.158.
2. Bischoff, S. C., Damms-Machado, A., Betz, C., Herpertz, S., Legenbauer, T., Löw, T., et al. (2012). Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life-a prospective study. International Journal of Obesity, 36, 614–624.
3. Calle, E. E., & Thun, M. J. (2004). Obesity and cancer. Oncogene, 23, 6365–6378.
4. Department for Business, Innovation and Skills. (2007). Annual review for 2007. http://www.bis.gov.uk/assets/foresight/docs/general-publications/annual-review-2007.pdf. Accessed 24 April 2012.
5. Helmiö, M., Salminen, P., Sintonen, H., Ovaska, J., & Victorzon, M. (2011). A 5-year prospective quality of life analysis following laparoscopic adjustable gastric banding for morbid obesity. Obesity Surgery, 21, 1585–1591.